David wants understanding between NHS & industry

Not who you say I am: Pharma companies need to be clear who they’re talking to and why they’re talking to them. Last week a pharma...

Two takes: Bad habits – help or hindrance?

  In this month’s emotive opinion battle, we ask two healthcare professionals if we should be encouraging patients to evaluate their lifestyle choices, or are...

Pharmacists are the last step between HCPs and patients

Having the right medicine at the right time and administered in the right way can be the difference between that patient continuing their treatment...

AI is launching healthcare into the future

With tales of Victorian era conditions on hospital wards, chronic ambulance queues and surgery delays reminiscent of the NHS’s nadir in the early 1990s,...

Does a pharmacy career appeal to young people?

  For pharmacy graduates forcing doors open is essential. Over 30 years ago I made the decision to study pharmacy at Nottingham University, with little understanding...

Tracking progress of the Rare Disease Strategy

February’s magazine focused on rare diseases, but how can implementation plans for the Rare Disease Strategy be properly monitored? The Rare Disease Strategy implementation plans...

Outcome-based contracts for medicines: What’s the deal?

  Outcome-based contracts for medicines – is there enough financial headroom to attract pharma? In the January and February issues of Pf Magazine we discussed the...

Are women losing out on pharmacy’s top jobs?

  The majority of pharmacy’s workforce are women, so why do men continue to secure the top jobs? I’m writing this on a train returning home...

NHS’s prophecy is threatened as the game changes

  This year is the 70th anniversary of the NHS; that embodiment of the Good Samaritan parable admirably rooted in the Christian socialism of 1940s...

What’s the future for healthcare data?

  We’re just getting used to it, but will healthcare data become federated in the future? An overwhelming trend in 2018 will be increasing restrictions around...

Latest articles

NHS trusts face worryingly high levels of senior vacancies

Why is high turnover among board-level roles make a negative impact on the performance of NHS trusts?

Triumph for Roche’s flu drug in phase III study

Roche has announced that the phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications...

Leading Alzheimer’s Disease scientist joins NeuroCog Trials

Dr. Kathleen Anne Welsh-Bohmer, a specialist in Alzheimer’s Disease research, has joined the scientific leadership team at NeuroCog Trials (NCT) as the Vice President...